<DOC>
	<DOCNO>NCT00827775</DOCNO>
	<brief_summary>1 . To determine cross sectional case-controlled cohort study 50 hemodialysis patient blood pressure elevation hemodialysis associate decreased endothelial cell function ( measure brachial artery flow mediate dilation endothelial progenitor cell number ) , novel mechanistic marker causal pathway detrimental cardiovascular outcome ; 2 . To determine lower blood pressure carvedilol 25 ESRD subject blood pressure elevation hemodialysis improve endothelial cell dysfunction surrogate mechanistic marker improve cardiovascular outcome .</brief_summary>
	<brief_title>Mechanisms Treatment Intradialytic Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>hemodialysis &gt; 30 day age 18 80 year old ability provide inform consent Primary nephrologist deem patient target dry weight Predialysis SBP &gt; 140 postdialysis SBP &gt; 130 Patients active wound Blood pressure unable measure routine mechanism upper extremity Change blood pressure medication previous 2 week Intolerance beta alphablockers pregnancy Resting heart rate &lt; 50 Life expectancy &lt; 6 month Current therapy carvedilol contraindication carvedilol ( ONLY intervention arm )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Hemodialysis</keyword>
</DOC>